



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

JAN 03 2003

RECEIVED

In re Application of:

Jaques Dumas et al.

Examiner: Desai, Rita J.

Serial No.: 09/777,920

Group Art Unit: 1625

Filed: February 7, 2001

Title: INHIBITION OF RAF KINASE USING QUINOLYL, ISOQUINOLYL OR PYRIDYL UREAS

I hereby certify that this correspondence is being deposited with the U.S. Postal Services as First Class Mail in an envelope addressed to Assistant Commissioner for Patents Washington, D.C. 20231 On: December 23, 2002

Name: Richard J. Traverso

SIGNATURE

DATE December 23, 2002

REPLY AND AMENDMENT AFTER FINAL UNDER 37 CFR §1.116

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the office action dated September 27, 2002, please amend the above identified application as indicated below and consider the remarks which follow.

IN THE CLAIMS

Please replace claims 31-33 with claims 34-36 as follows:


34. A compound selected from the group consisting of

application provides general preparative methods on pages 12-16 to guide one skilled in the art to prepare the claimed compounds. Numerous references are also identified on page 12 for obtaining the desired starting materials. The specification also discloses how to prepare pharmaceutical agents with the compounds of the invention and how to administer them on pages 16-21 of the specification. Pages 25-61 provide greater detail in preparing certain starting materials and intermediates as well as procedures to use these materials to prepare the claimed compounds. On pages 62-85, the synthesis of over 100 compounds is provided. In view of this general and detailed description, the specification clearly provides an enabling disclosure for the subject matter claimed.

It is respectfully submitted that Applicants' specification provides more than sufficient disclosure to objectively enable one of ordinary skill in the art to make and use the claimed compounds. Therefore, withdrawal of the rejection under 35 USC §112, first paragraph, and the allowance of all pending claims is respectfully requested.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,



Richard J. Traverso (Reg. No. 30,595)
Attorney/Agent for Applicant(s)

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza 1, Suite 1400
2200 Clarendon Boulevard
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: BAYER 15P3

Date: December 23, 2002
K:\Bayer\15P3\reply\12-23-02t